The neurotoxicity of misonidazole: pooling of data from five centres

Abstract

At the Gray Conference held at Cambridge in September 1977, all the clinical groups having experience in the administration of misonidazole (Ro–07–0582) to patients reported upon their findings. There was a general agreement that neurotoxicity—principally peripheral neuropathy—was the limiting factor in determining the amount of this promising radiosensitizing compound which could be given to patients. It was further agreed that a pooling of the clinical data would advance knowledge as to the safe conditions for use of misonidazole in radiotherapy.